Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

GlobeNewswire October 26, 2022

ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China

GlobeNewswire October 13, 2022

ObsEva Announces Progress on Restructuring Initiatives

GlobeNewswire September 13, 2022

ObsEva Receives Nasdaq Non-Compliance Notice

GlobeNewswire August 22, 2022

ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing

GlobeNewswire August 1, 2022

ObsEva Announces Corporate Updates

GlobeNewswire July 27, 2022

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

GlobeNewswire June 28, 2022

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

GlobeNewswire June 17, 2022

ObsEva Announces Corporate Updates

GlobeNewswire May 27, 2022

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

GlobeNewswire May 25, 2022

ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

GlobeNewswire May 19, 2022

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022

GlobeNewswire May 19, 2022

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 17, 2022

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

GlobeNewswire May 16, 2022

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

GlobeNewswire May 12, 2022

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting

GlobeNewswire May 9, 2022

ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

GlobeNewswire May 2, 2022

ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

GlobeNewswire April 25, 2022

ObsEva Annual General Meeting 2022

GlobeNewswire April 7, 2022

ObsEva Annual Report 2021

GlobeNewswire March 31, 2022